Trial Profile

A multicenter Phase 3 clinical trial evaluating effect of Boluojia

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 14 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Denosumab (Primary)
Indications Giant cell tumour of bone
Focus Pharmacokinetics; Therapeutic Use

Most Recent Events

14 Jun 2024 According to Boan's Boluojia media release, the company announced that after the completion of this study, Boan Biotech will submit a BLA to the European Medicines Agency (EMA), the U.S. Food and Drug Administration (FDA), and Japans Pharmaceuticals and Medical Devices Agency (PMDA) respectively for all approved indications of the reference product
14 Jun 2024 New trial record
27 May 2024 According to Boan's Boluojia media release, results of this clinical trial were presented at the 2023 Annual Meeting of American Society of Clinical Oncology (ASCO) in the form of a poster.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com